A. V. van Vliet

Publications27
h-index15
Citations1,619
Highly Influential Citations53
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Zeuzem
  • 1,900 Publications • 100,773 Citations
  • H. Reesink
  • 393 Publications • 17,746 Citations
  • H. Janssen
  • 849 Publications • 37,530 Citations
  • J. McHutchison
  • 730 Publications • 74,552 Citations
  • Publications
  • Influence
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
TLDR
VX-950 was well tolerated and demonstrated substantial antiviral activity in patients with chronic hepatitis C, and some patients had viral breakthrough during dosing, related to selection of variants with decreased sensitivity to VX- 950.
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
TLDR
In critically ill surgical patients with severe IAIs, CI of ceftazidime resulted in more favourable concentrations in serum and peritoneal exudate than 8-hourly bolus infusion.
Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation
TLDR
The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
TLDR
Once daily TMC435 given orally was generally safe and well tolerated and demonstrated potent antiviral activity, in a first-in-human trial.
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
TLDR
Narlaprevir administration resulted in a robust HCV‐RNA decline and high SVR rates when followed by standard of care in both treatment‐experienced and treatment‐naïve HCV genotype 1–infected patients.
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report
TLDR
Although the underlying cause of toxicity was not clinically obvious, giving antimicrobial therapy resulted in an improvement in the patient's clinical condition and indicates the value of serum levels of C-reactive protein and desmethylclozapine, major metabolite of clozapines, in the treatment of aetiologically unclear clozAPine toxicity.
...
1
2
3
...